Condition: Ulcerative Colitis Chronic Moderate · Ulcerative Colitis Chronic Severe · Sponsor: Protagonist Therapeutics, Inc.
The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of PN-943 450 mg twice daily \[BID\] and PN-943 150 mg BID, compared with placebo BID, in subjects with moderate to severe active Ulcerative Colitis (UC).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Protagonist Investigational Site | Tucson, Arizona, United States | — |
| Protagonist Investigational Site | Garden Grove, California, United States | — |
| Protagonist Investigational Site | Los Angeles, California, United States | — |
| Protagonist Investigational Site | Murrieta, California, United States | — |
| Protagonist Investigational Site | San Francisco, California, United States | — |
| Protagonist Investigational Site | Colorado Springs, Colorado, United States | — |
| Protagonist Investigational Site | Kissimmee, Florida, United States | — |
| Protagonist Investigational Site | Miami, Florida, United States | — |
| Protagonist Investigational Site | Miami, Florida, United States | — |
| Protagonist Investigational Site | Miami, Florida, United States | — |
| Protagonist Investigational site | Orlando, Florida, United States | — |
| Protagonist Investigational Site | Saint Augustine, Florida, United States | — |
+ 110 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04504383